Exhibit 99.2
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of PharmaCyte Biotech, Inc., a Nevada corporation. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
Dated: August 15, 2022
| IROQUOIS MASTER FUND LTD. | |||
| By: | Iroquois Capital Management, LLC, | ||
| its investment manager | |||
| By: |
/s/ Richard Abbe | ||
| Name: | Richard Abbe | ||
| Title: | President | ||
| IROQUOIS CAPITAL MANAGEMENT, LLC | |||
| By: |
/s/ Richard Abbe | ||
| Name: | Richard Abbe | ||
| Title: | President | ||
| IROQUOIS CAPITAL INVESTMENT GROUP LLC | |||
| By: |
/s/ Richard Abbe | ||
| Name: | Richard Abbe | ||
| Title: | Managing Member | ||
|
/s/ Richard Abbe | |
| RICHARD ABBE |
|
/s/ Kimberly Page | |
| KIMBERLY PAGE |